A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

NCT05506410 · clinicaltrials.gov ↗

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed Mantle Cell Lymphoma

Interventions

DRUG: Rituximab

Sponsor

Zhengzhou University